13F reference period
Q2 2026
Security Snapshot
Fortress Biotech, Inc. - Common Stock, par value $0.001 per share (FBIO) Institutional Ownership
CUSIP: 34960Q307
13F Institutional Holders and Ownership History from Q3 2023 to Q3 2026
Institutions Reporting
55
Shares (Excl. Options)
5.79M
Full value: 5,792,875 · shares · 30 Jun 2026Price
$3.06
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- FBIO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 5,792,875
- Total 13F value
- $17,725,609
- Portfolio coverage rank
- 0%
- Share change
- +433,591
- Value change
- +$1,378,210
- Number of holders
- 55
- Shares outstanding
- 33,313,862
- SEC-reported price per share
- $1.95
- Insider filing price
- $1.95
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- FBIO - Fortress Biotech, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 34960Q307.
- 55 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 52 to 55 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$14.95M
Full value: $14,951,860 · USD · 31 Mar 2026.$17.73M
Full value: $17,725,609 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 55 institutions filings for Q2 2026.
Security key
34960Q307
13F reference period
Q2 2026
13F holders
55
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
FBIO full holder history
Fortress Biotech, Inc. SEC filings
Fortress Biotech, Inc. company facts
Fortress Biotech, Inc. insider transactions
Fortress Biotech, Inc. 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 34960Q307:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
FBIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| INTEGRATED CORE STRATEGIES (US) LLC | 6.5% | +24% | $4,633,958 | +$827,838 | 2,165,401 | +22% | Millennium Management LLC | 30 Sep 2026 |
As of 30 Jun 2026,
55
institutional investors reported holding
shares of
Fortress Biotech, Inc. - Common Stock, par value $0.001 per share (FBIO).
This represents
17%
of the company’s total
outstanding shares.
5.79M
Full value: 5,792,875 · shares · 30 Jun 202633.31M
Full value: 33,313,862 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
16%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 1,037,203 | +7.4% | 0% | $3,173,841 |
| Opaleye Management Inc. | 2.7% | 890,000 | -15% | 0.25% | $2,723,400 |
| MACKENZIE FINANCIAL CORP | 1.7% | 555,676 | 0% | $1,700,369 | |
| GSA CAPITAL PARTNERS LLP | 1.4% | 458,472 | +80% | 0.09% | $1,403,000 |
| SHIKIAR ASSET MANAGEMENT INC | 0.92% | 305,469 | 0% | 0.24% | $935,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.9% | 300,521 | +3.5% | 0% | $919,944 |
| BlackRock, Inc. | 0.67% | 224,782 | +14% | 0% | $687,833 |
| TWO SIGMA INVESTMENTS, LP | 0.64% | 213,786 | +8.6% | 0% | $654,185 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.53% | 177,368 | -2.7% | 0.01% | $542,746 |
| VANGUARD FIDUCIARY TRUST CO | 0.5% | 166,371 | +17% | 0% | $509,095 |
| HB Wealth Management, LLC | 0.35% | 116,675 | -2.9% | 0% | $357,026 |
| Kestra Advisory Services, LLC | 0.35% | 116,235 | -10% | 0% | $355,679 |
| ACADIAN ASSET MANAGEMENT LLC | 0.32% | 107,303 | +165% | 0% | $327,000 |
| STATE STREET CORP | 0.3% | 101,601 | 0% | 0% | $310,899 |
| GOLDMAN SACHS GROUP INC | 0.29% | 96,358 | 0% | $294,855 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.26% | 86,390 | -13% | 0% | $264,353 |
| CITADEL ADVISORS LLC | 0.23% | 77,065 | -57% | 0% | $235,819 |
| Integrated Quantitative Investments LLC | 0.21% | 68,692 | 0.03% | $210,198 | |
| PANAGORA ASSET MANAGEMENT INC | 0.2% | 66,025 | +17% | 0% | $202,037 |
| NORTHERN TRUST CORP | 0.19% | 63,632 | -72% | 0% | $194,714 |
| 180 WEALTH ADVISORS, LLC | 0.18% | 61,600 | -3.4% | 0.02% | $188,496 |
| UBS Group AG | 0.16% | 52,346 | +262% | 0% | $160,179 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.14% | 47,002 | -78% | 0% | $143,826 |
| Integrated Wealth Concepts LLC | 0.14% | 45,200 | 0% | 0% | $138,312 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.12% | 41,507 | 0.01% | $127,011 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Headline period
Q2 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 463,294 | $991,746 | -$59,649 | $2.14 | 4 |
| 2026 Q2 | 5,792,875 | $17,725,609 | +$1,378,210 | $3.06 | 55 |
| 2026 Q1 | 5,359,286 | $14,951,860 | -$1,567,086 | $2.79 | 52 |
| 2025 Q4 | 5,776,667 | $21,167,908 | +$5,142,594 | $3.66 | 50 |
| 2025 Q3 | 4,466,852 | $16,462,217 | -$434,387 | $3.70 | 56 |
| 2025 Q2 | 4,960,694 | $9,226,455 | +$452,125 | $1.86 | 49 |
| 2025 Q1 | 4,912,339 | $7,662,384 | +$48,360 | $1.56 | 46 |
| 2024 Q4 | 4,817,545 | $9,770,551 | +$1,056,686 | $2.02 | 53 |
| 2024 Q3 | 4,447,052 | $6,425,387 | +$1,136,322 | $1.44 | 49 |
| 2024 Q2 | 3,624,236 | $6,212,160 | +$1,214,303 | $1.71 | 50 |
| 2024 Q1 | 2,786,648 | $5,571,004 | -$5,820,776 | $2.00 | 38 |
| 2023 Q4 | 4,683,824 | $14,095,638 | +$8,417,966 | $3.01 | 42 |
| 2023 Q3 | 2,552,013 | $741,000 | +$741,000 | $0.29 | 2 |